Changing business models for pharmaceutical industry
This page is under construction and edited by Murat Akguc EMBA09. In case of any questions/remarks, feel free to contact me
GaMOX1 <a href="http://iqlvgztznwqt.com/">iqlvgztznwqt</a>, [url=http://hncjlqeqbhrl.com/]hncjlqeqbhrl[/url], [link=http://rrjddzgcysui.com/]rrjddzgcysui[/link], http://dulbklunnfnm.com/
Enablers:
- Increasing Cost of R&D
- Struggling old world economy
- Increasing Private Funding (Venture Capital) for Biotech Research and Start-up financing
- Increasing Willingness and/or Ability of Governments to Sponsor Biotech Research
- Increasing Consolidation and Alliances among Pharma Companies
Inhibitors:
- Low Entry Barriers
- Increasing Patent Expiries for Blockbusters
- Competition from Generics
- Insufficient connectivity between the key players Decline of (R&D) cooperation between public and private
Paradigms:
Big Pharma Companies will need to improve their R&D productivity, reduce their costs, tap the potential of the emerging economies and switch from selling medicines to managing outcomes.
Experts:
Sources for additional information about this driving force. (if you have found people, put the links to them)
Timing:
Web Resources:
[1] Business Model of the Information Age Pharmaceutical Industry, The Information Management Group (http://www.img.ch/upload/63001e_White_Paper_Business_Model_of_the_Information_AGE_-_Pharmaceutical_Industry_282.pdf)
- Pharma 2020: Challenging business models, PricewaterhouseCoopers, (http://www.pwc.com/gx/en/pharma-life-sciences/pharma-2020-business-models/index.jhtml)
- Pharma 2020: Virtual R&D "Which path will you take?", PricewaterhouseCoopers,http://www.pwc.com/gx/en/pharma-life-sciences/pharma-2020/pharma2020-virtual-rd-which-path-will-you-take.jhtml
- Sustaining Competitiveness through Alliances and Innovation: The impact of Alliance Management Issues on learning skills and competencies from partner(s), Prof. S. Raghunath (Email), Thomas Joseph (Email), (http://dspace.iimk.ac.in/bitstream/2259/492/1/349-358+.pdf)